FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
arcticnovartis
Tue, 10/31/2023 – 22:04
Read more about FDA approves Novartis Cosentyx® as the first new biologic tre…
Novartis investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 10/30/2023 – 07:34
Read more about Novarti…
Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
arcticnovartis
Thu, 10/26/2023 – 22:19
Read more about Novartis confirms unconstrained supply for Pluvicto® and continues to …
Novartis steigert Umsatz um 12% und operatives Kernergebnis um 21% (fortzuführende Geschäftsbereiche, kWk¹). Sandoz abgespalten, wichtige Innovationsmeilensteine erreicht und Prognose 2023 erhöht
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more abo…
Novartis delivers 12% sales and 21% core operating income growth from continuing operations (in cc¹). Executes Sandoz spin-off, achieves important innovation milestones, and raises FY 2023 guidance
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more a…
Novartis : hausse de 12% du chiffre d’affaires et de 21% du résultat opérationnel core (tcc¹). Spin-off de Sandoz, étapes importantes de l’innovation ; hausse des prévisions pour 2023
arcticnovartis
Tue, 10/24/2023 – 07:03
Read more about Novartis …
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
arcticnovartis
Mon, 10/23/2023 – 16:34
Read mo…
Novartis Pluvicto™ shows clinically meaningful and highly statistically significant rPFS benefit in patients with PSMA-positive metastatic castration-resistant prostate cancer in the pre-taxane setting
arcticnovartis
Mon, 10/23/2023 – 16:32
Read mo…
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
Fri, 10/20/2023 – 12:04
Read more about Novartis Kisqali® NATALEE analysis reinforces …
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis
Fri, 10/20/2023 – 12:03
Read more about Novartis Kisqali® NATALEE analysis reinforces …
